Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551358 | 0.92 | HDAC2 (0.59) | HDAC1PTGS1HDAC2HDAC3NCOR1 | |
| SCHEMBL3551891 | 0.88 | HDAC1 (0.55) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3551917 | 0.86 | HDAC2 (0.59) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3555561 | 0.84 | HDAC1 (0.59) | HDAC1HDAC2HDAC3NCOR1HDAC4 | |
| SCHEMBL3550162 | 0.84 | HDAC2 (0.54) | HDAC1HDAC2HDAC3 | |
| SCHEMBL3558649 | 0.82 | HDAC2 (0.61) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3551291 | 0.82 | HDAC2 (0.63) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3544162 | 0.81 | HDAC2 (0.57) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3553156 | 0.81 | HDAC1 (0.58) | HDAC1PTGS1HDAC2 | |
| SCHEMBL16083166 | 0.80 | HDAC2 (0.71) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | claimed |
| CN-101263121-A | Histone deacetylase inhibitors | TAKEDA SAN DIEGO INC (US) | 2008-09-10 | — | — | CN | claimed |
| EP-1904452-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2007011626-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | claimed |
| US-7741494-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741494-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741494-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20090111996-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-08 | — | — | US | disclosed |
| EP-1904452-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007011626-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011626-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC1 1/4885PTGS1 3189/4885HDAC2 4/4885 |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC1 1/4885PTGS1 3189/4885HDAC2 4/4885 |
| US-20090111996-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC1 1/4885PTGS1 3189/4885HDAC2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.